<DOC>
	<DOCNO>NCT00863499</DOCNO>
	<brief_summary>The aim iSPOT-A study : 1. identify brain , genetic cognitive marker Attention Deficit/Hyperactivity Disorder , 2. identify brain , genetic cognitive marker predict treatment response short-acting methylphenidate child adolescent diagnose Attention Deficit/Hyperactivity Disorder .</brief_summary>
	<brief_title>International Study Predict Optimised Treatment Attention Deficit/Hyperactivity Disorder</brief_title>
	<detailed_description>This multi-center , open-label effectiveness trial identify objective indicator treatment response ADHD subject ( versus healthy control ) use cognitive brain function measure , brain structure genetic measure subject diagnose ADHD . At least 672 naïve treatment experienced subject ADHD enrol approximately 10 primary care center . These patient outpatient . In addition , 672 healthy ( non-ADHD ) control subject recruit match enrol ADHD subject race , age , gender year education .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>Subjects sign informed consent assent form require and/or whose parent legal guardian provide write informed consent . Subjects meet DSMIV criterion primary diagnosis ADHD study entry , determine psychiatrist , physician clinical psychologist conjunction clinical workup undertaken train research assistant , define The Mini International Neuropsychiatric Interview Children Adolescents ( MINI Kid ) . Subjects score least 6 Inattentive Hyperactive/impulsive item &gt; 1 Attention Deficit / Hyperactivity Disorder Rating Scale . Subjects stimulant naïve stimulant free ( defined stimulant medication previous 7 days* ) . Subjects 617 year age ( emphasis enrol least third subject ≥ 13 year age ) . Subjects fluent literate English ( and/or Dutch The Netherlands ) . come stimulant medication 7 day may place participant increase risk , therefore , participant may washout period reduce defined drug package insert 5 time medication half life . Known contraindication intolerance use methylphenidate define product package insert ( include previous treatment failure high recommend dose ) . Pregnancy females child bear potential use form contraception risk become pregnant study . Known medical condition , disease neurological disorder might , opinion investigator/s , interfere assessment make study put ADHD patient increase risk expose optimal dos drug treatment . For example , diagnosis epilepsy would exclude patient trial . History physical brain injury blow head result loss consciousness least 10 minute least 5minutes within last two year . Prior treatment methylphenidate stimulant medication past 7 day . Known past present substance dependence , include alcohol , determine The Mini International Neuropsychiatric Interview Children Adolescents ( MINI Kid ) . Participation investigational study within four month baseline visit subject receive experimental drug/device could affect primary end point study . Use psychological counselling therapy CNS medication wash prior participation use psychological counselling therapy baseline week 6 ( Early Termination ) visit . Subjects , opinion investigator , severe impediment vision , hear and/or hand movement , likely interfere ability complete test battery . Subjects , opinion investigator , unable and/or unlikely comprehend follow study procedure instruction . Presence comorbid primary DSM IV disorder .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Attention Deficit/Hyperactivity Disorder</keyword>
	<keyword>Attention Deficit Disorder</keyword>
	<keyword>ADHD</keyword>
	<keyword>ADD</keyword>
	<keyword>iSPOT</keyword>
</DOC>